169 related articles for article (PubMed ID: 1705647)
1. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis.
Nunn P; Kibuga D; Gathua S; Brindle R; Imalingat A; Wasunna K; Lucas S; Gilks C; Omwega M; Were J
Lancet; 1991 Mar; 337(8742):627-30. PubMed ID: 1705647
[TBL] [Abstract][Full Text] [Related]
2. Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania.
Dukes CS; Sugarman J; Cegielski JP; Lallinger GJ; Mwakyusa DH
Trop Geogr Med; 1992 Oct; 44(4):308-11. PubMed ID: 1284179
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-I.
Chintu C; Luo C; Bhat G; Raviglione M; DuPont H; Zumla A
Arch Dis Child; 1993 May; 68(5):665-8. PubMed ID: 7686737
[TBL] [Abstract][Full Text] [Related]
4. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration.
Okwera A; Whalen C; Byekwaso F; Vjecha M; Johnson J; Huebner R; Mugerwa R; Ellner J
Lancet; 1994 Nov; 344(8933):1323-8. PubMed ID: 7526098
[TBL] [Abstract][Full Text] [Related]
5. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon.
Kuaban C; Bercion R; Koulla-Shiro S
East Afr Med J; 1997 Aug; 74(8):474-7. PubMed ID: 9487410
[TBL] [Abstract][Full Text] [Related]
6. Adverse cutaneous reactions to thiacetazone for tuberculosis treatment in Tanzania.
Ipuge YA; Rieder HL; Enarson DA
Lancet; 1995 Sep; 346(8976):657-60. PubMed ID: 7544858
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson syndrome during anti-tuberculosis chemotherapy in HIV-seropositive patients: report on six cases.
Wirima JJ; Harries AD
East Afr Med J; 1991 Jan; 68(1):64-6. PubMed ID: 2060484
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ
Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099
[TBL] [Abstract][Full Text] [Related]
9. Life-threatening cutaneous reactions to thiacetazone-containing antituberculosis treatment in Kumasi, Ghana.
Lawn SD; Frimpong EH; Acheampong JW
West Afr J Med; 1999; 18(4):249-53. PubMed ID: 10734785
[TBL] [Abstract][Full Text] [Related]
10. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya.
Hawken M; Nunn P; Gathua S; Brindle R; Godfrey-Faussett P; Githui W; Odhiambo J; Batchelor B; Gilks C; Morris J
Lancet; 1993 Aug; 342(8867):332-7. PubMed ID: 7687729
[TBL] [Abstract][Full Text] [Related]
11. The influence of HIV status on single and multiple drug reactions to antituberculous therapy in Africa.
Pozniak AL; MacLeod GA; Mahari M; Legg W; Weinberg J
AIDS; 1992 Aug; 6(8):809-14. PubMed ID: 1384557
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
13. Multiforme skin lesions in Yekatit 12 Hospital, 1976-1994.
Gessesse B; Mulugeta E
Ethiop Med J; 2000 Jan; 38(1):43-7. PubMed ID: 11144879
[TBL] [Abstract][Full Text] [Related]
14. Severe hypersensitivity reactions among HIV-seropositive patients with tuberculosis treated with thioacetazone.
Wkly Epidemiol Rec; 1992 Jan; 67(1-2):1-3. PubMed ID: 1371055
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya.
van Gorkom J; Kibuga DK
Tuber Lung Dis; 1996 Feb; 77(1):30-6. PubMed ID: 8733411
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous hypersensitivity reactions to thiacetazone, HIV infection and thiacetazone concentrations in plasma.
Watkins WM; Mungai M; Muhia DK; Mberu EK; Gathua S; Winstanley PA; Gilks CF; Nunn P
Br J Clin Pharmacol; 1996 Feb; 41(2):160-2. PubMed ID: 8838444
[TBL] [Abstract][Full Text] [Related]
17. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire.
Perriëns JH; Colebunders RL; Karahunga C; Willame JC; Jeugmans J; Kaboto M; Mukadi Y; Pauwels P; Ryder RW; Prignot J
Am Rev Respir Dis; 1991 Oct; 144(4):750-5. PubMed ID: 1928943
[TBL] [Abstract][Full Text] [Related]
18. Current HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone-free antituberculosis treatment in Yaounde, Cameroon.
Kuaban C; Bercion R; Koula-Shiro S
Cent Afr J Med; 1998 Feb; 44(2):34-7. PubMed ID: 9675969
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous sensitivity to thiacetazone.
Fegan D; Glennon J
Lancet; 1991 Apr; 337(8748):1036. PubMed ID: 1708068
[No Abstract] [Full Text] [Related]
20. Human immunodeficiency virus type-1 infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thioacetazone-free regimen.
Luo C; Chintu C; Bhat G; Raviglione M; Diwan V; DuPont HL; Zumla A
Tuber Lung Dis; 1994 Apr; 75(2):110-5. PubMed ID: 8032043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
